Quest Diagnostics Inc. (DGX)
Quest Diagnostics CEO: AI is helping patients understand their doctors
Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #ai #artificialintelligence #health #healthcare #technology #medical #patients #doctors #diagnostics #innovation #business #leadership #future #medicine #jimdavis #questdiagnostics
Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates
DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.
Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?
Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.
Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026
DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) is a Great Choice
Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics Q2 Earnings Call Highlights
Quest Diagnostics NYSE: DGX reported double-digit revenue growth and raised its full-year 2026 outlook after what executives described as strong demand across its physician, hospital and consumer channels, as well as increased volume from major collaborations with Corewell Health and Fresenius Medical Care.
DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised
Quest Diagnostics shares rise as second-quarter earnings and revenues beat estimates, testing demand surges and the company raises its 2026 outlook.
Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.62 per share a year ago.
Quest Diagnostics raises annual forecast on testing demand
Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates.
